<SEC-DOCUMENT>0001104659-22-005158.txt : 20220119
<SEC-HEADER>0001104659-22-005158.hdr.sgml : 20220119
<ACCEPTANCE-DATETIME>20220119070550
ACCESSION NUMBER:		0001104659-22-005158
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220119
FILED AS OF DATE:		20220119
DATE AS OF CHANGE:		20220119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adagene Inc.
		CENTRAL INDEX KEY:			0001818838
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39997
		FILM NUMBER:		22536783

	BUSINESS ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
		BUSINESS PHONE:		86-512-87773632

	MAIL ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm223354d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of January 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39997</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Adagene Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its
Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4F, Building C14, No.&nbsp;218</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Xinghu Street, Suzhou Industrial Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suzhou, Jiangsu Province, 215123</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>People&#8217;s Republic of China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+86-512-8777-3632</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;20-F
</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp; <B>&nbsp;</B>Form&nbsp;40-F
</FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Adagene
    Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 46%; padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Peter (Peizhi) Luo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Peter
    (Peizhi) Luo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: January 19, 2022</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 87%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="tm223354d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="tm223354d1_ex99-1.htm">Press Release titled "Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D."</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: white">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm223354d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="tm223354d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Adagene Expands Scientific and Strategic Advisory
Board with Appointment of David Gandara, M.D.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Dr.&nbsp;Gandara, Professor and Senior Advisor
to the Thoracic Oncology Program at University of California <BR>
Davis, brings deep expertise and strategic vision in cancer drug and biomarker
development-</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SAN
DIEGO and SUZHOU, China, January&nbsp;19, 2022&nbsp;&ndash; Adagene Inc. (&ldquo;Adagene&rdquo;) (Nasdaq: ADAG), a biotech company
committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced the appointment of David
Gandara, M.D.,</FONT> to its Scientific and Strategic Advisory Board (the &ldquo;SAB&rdquo;). Dr.&nbsp;Gandara, Professor Emeritus and
Senior Advisor of the Thoracic Oncology Program at University of California Davis Comprehensive Cancer Center (UCDCCC), brings deep knowledge
and understanding to the immuno-oncology field, and he is recognized for his translational research and clinical work in cancer drug and
biomarker development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr.&nbsp;Gandara commented, &quot;I am delighted to join Adagene&rsquo;s
SAB at such an exciting time in the company's evolution. Adagene&rsquo;s innovative antibody-based technology platform has the potential
to advance the next generation of immuno-oncology treatments. I look forward to working alongside the impressive team to execute on the
company&rsquo;s mission to bring transformative new cancer therapeutics to patients around the world.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are thrilled to welcome Dr.&nbsp;Gandara to our SAB as a
leading researcher and physician, as well as a thought leader in biomarker-driven strategies for lung cancer therapies,&rdquo; said Peter
Luo, Ph.D., Co-Founder, Chief Executive Officer and Chairman of the Board of Adagene. &ldquo;We look forward to Dr.&nbsp;Gandara&rsquo;s
insights, especially on the heels of the recently initiated trial in Singapore evaluating ADG106 in combination with Nivolumab in patients
with advanced non-small cell lung cancer. More broadly, we value his inputs as we accelerate the global clinical development of our rapidly
expanding pipeline, including novel combination therapies. Together we look forward to maximizing the potential of our platform to transform
immunotherapy for cancer patients across the world.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr.&nbsp;Gandara has received numerous awards, authored over 450 publications,
and presented his work at meetings nationally and internationally. He is a co-leader at Lung MAP, a precision medicine umbrella clinical
trial for the development of biomarker-driven strategies for new therapies in lung cancer. His current research includes the development
of preclinical modeling and clinical research in lung cancer. Recently, he was appointed Chief Medical Officer of the International Society
for Liquid Biopsy. Prior to his present roles, he was president of the International Association for Study of Lung Cancer, as well as
treasurer and BOD member of the American Society of Clinical Oncology (ASCO). He has previously served as chair of the Lung Committee
for the Southwest oncology group (SWOG) and is founding co-chair of the NCI Investigational Drug Steering Committee (IDSC). Dr.&nbsp;Gandara
obtained his M.D. from University of Texas Medical Branch at Galveston, and he completed his clinical training as a resident at Madigan
Army Medical Center, and as a Fellow in hematology and oncology at Letterman Army Medical Center. He received his B.A. at the University
of Texas, Austin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information about members of the Adagene Scientific and Strategic
Advisory Board, visit: https://www.adagene.com/about/key-advisors/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm223354d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Adagene</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotech
company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational
biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision
Library (DPL) platform, composed of NEObody&trade;, SAFEbody<SUP>&reg;</SUP>, and POWERbody<SUP>&trade;</SUP> technologies, Adagene&rsquo;s
highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global
partners that leverage its technology in multiple approaches at the vanguard of science.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, please visit:&nbsp;</FONT>https://investor.adagene.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212121">SAFEbody<SUP>&reg;</SUP>
is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Safe Harbor Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements, including statements
regarding the potential implications of clinical data for patients, and Adagene&rsquo;s advancement of, and anticipated clinical activities,
clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from
those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene&rsquo;s
ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support
further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding
regulatory approval of Adagene&rsquo;s drug candidates; Adagene&rsquo;s ability to achieve commercial success for its drug candidates,
if approved; Adagene&rsquo;s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene&rsquo;s
reliance on third parties to conduct drug development, manufacturing and other services; Adagene&rsquo;s limited operating history and
Adagene&rsquo;s ability to obtain additional funding for operations and to complete the development and commercialization of its drug
candidates; Adagene&rsquo;s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations,
and the impact of the COVID-19 pandemic on Adagene&rsquo;s clinical development, commercial and other operations, as well as those risks
more fully discussed in the &ldquo;Risk Factors&rdquo; section in Adagene&rsquo;s filings with the U.S. Securities and Exchange Commission.
All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be
required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Internal
Contact</B></FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ami Knoefler<BR>
Adagene<BR>
650-739-9952<BR>
ir@adagene.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>External Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bruce Mackle<BR>
LifeSci Advisors<BR>
646-889-1200<BR>
bmackle@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm223354d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm223354d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T +8# 2(  A$! Q$!_\0
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M61,H^=C$9Y'I1[!^TY+F5;'QI89U^6]M+?.QZ!17 )X$U%XU?^W7&X ]&_\
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M.O:/#>I#6/#6G7^<M- I?_>QAOU!KF-=NO#L_P /[C1(-9TYFCLPD0%PG+(
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M@#]XUN)/#(VU)48]<*P->>Z)X%M-5T:VOI+R9'F4DJJC Y(_I71:%X/MM!U
MW<-U+*QC,>UP ,$@]OI45(PNW?7T.K UL6Z=.+IKELM>;I;>UCI****P/6"O
M#-&TJW^(/Q%U>6[>7[&-\F8VP< A$&?I_*O;+R![FQN+>.4PO+&R+(!G82,9
MQ[5S?@OP1#X.6[*7C74ESL!=HPFT+GCJ?6MZ4U",GUZ')B*3JS@FO=6K,I_@
M_P"&RC!)+X-C@F8<'_OFL/X.WKVNIZOHD_#C$H4]F4[&_FOY5ZY7&V/@%-/\
M;2^([?477S9'=K;RA@[QR-V?7GI3C6YH2C-^A,\,H5(3I1M;?T.*US_DNUK_
M -?%O_Z *]9U36+#1K*2[O[J.&)!GYFY;V [GVKCO$WPQC\1Z_/JIU:2W:4(
M/+6 -C:H'7</2L^W^#%@)E:\UBZG0=52,(3^))JI.E-1O+9=B(1KTY3Y8WN[
M[F7\,[>?7/'6I^(I(RL2F1L]M\AX7\%S^E5M6M8_&OQ@DT^5G^R1$PN4."%C
M4[L'_>R/QKU_2])LM%TY+'3H%@@3HHYR?4GJ3[US?A7P#'X:UJZU5]1>\GN$
M93NB";2S;B>IZXI^W7-*6VED)X27)"F]5>\BE_PJ#PS_ '[_ /[_ (_^)KF/
MA\3X=^)>I:$S'RY/,A3<>I0[D/\ WSG\Z]EKC;_P"EWXVB\30ZB]O*CQNT(B
M!#%1@\Y[CBHA6;4HS>Z+J851E&=&.J?X&1XJW:/XZM=3=287,<F1WV_*P^N/
MYUZ+!/%<P)/#(LD3C<KJ<@BJFK:/9ZU9FVNT)7.5=>&0^H-<B?AU.A*0:RZP
M'JIC/]&P:+PJ12D[-'*J>)PE:I*E#GC-WWLT_GT*!FCN_BBDENPD3SP-R\CA
M,'^1JQ\2_P#CZT__ *YO_,5U&@>%K'0 TD1::Y88:9QR!Z =A4?B3PLOB&6W
M=KMH/)5A@)NSG'N/2K56'M$^B5CFGE^(>"J1:7/.7-;MKW-NW(^S1<_P#^52
MY%<)_P *W7_H+R_]^O\ [*M+0_!BZ+J:WHU!YMJLNPQXZ_C6,HT[74OP/0I8
MC%N2C.C9=^9&!J__ "5&V_ZZP_R%=MKVEKK&BW%F0-[+F,GLXY%9]WX42Z\3
MQZT;QE9'1O*\O(.T8ZY]JZ*G.HO=<>B(PF$DO;QJK2<G]S1XMH\DK^(]+68G
M=%<1Q@'JH#=/PKO?B)_R+:?]?*?R:GS>"H)/$0U:.[:/$RS&$1Y!8$$\Y[G^
M=:GB#1%U[3EM&G,($@DW!=W0'CK[UK.K&4XR['#ALNKTL+7HM7<MM=R#P@1_
MPB>G_P"X?_0C6YD>M<(/AL@&!JTH_P"V/_V53V7P_6SOK>Z_M21_)D63:8L9
MP<XZUG*--MOF_ [,/5QE.$:;H[)*_,O0[2BBBL#U@HHHH **** "BBB@ HHH
DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
